Expression of Grouth- Related Oncogen-a protein in rat asthma model and effects of dex amethasone

Abstract

Abstract: AIM: To observe the expressions of Grouth-Related Oncogen-a(GROa) in rat asthma model and effects of dexamethasone. METHODS: In this experiment, the rat model of asthma were randomly divided into three groups on average, incuding asthma group，control group and dexamethasone treated group.Blood PMN were isolated and purified.The expressions of GROa protein in bronchial wall and in blood PMN were detected by immunohistochemical method. Numbers of PMN were calculated in lung tissue. RESULTS: Levels of GROa protein in asthma group(0.138±0.009,Optical density) and in dexamethasone treated group(0.105±0.012, Optical density)were significant higher than those in control group(0.077±0.010，Optical density) (P<0.01) in bronchial wall. And levels of GROa protein in dexamethasone treated group were significantly decreased compared to asthma gnoup(PK 0.01). While in blood PMN，The expressions of GROa protein in asthma group(0.211土0.017, Optical density) and in dexamethasone treated goup(0.128±0.012, Optical densirty) were significant higher than those in control group(0.081±0.008，Optical density)(P<0.01). And levels of GROa protein in dexamethasone treated group were significantly decreased compared to asthma group(P<0.01). And the levels of G ROa protein in bronchial wall and blood PMN were significant different between dexamethasone treated group and those in asthma group(P<0.01). There numbers of PMN in lung tissue were significant different among three goups, in control group (7±2)< in asthma group(26±6)CONCLUSION: In bronchial wall and in blood PMN，levels of GROa protein were increased in rat asthma. And numbers of PMN in lung tissue were increased either. They are involved in inflammation of rat asthma model. The decreased inflammation of asthma by dexamethasone maybe via decreased synthesis of GROa protein. But dexamethasone can increasing PMN influxing into lung tissue. The influx of PMN into lung tissue may be corelated with GROa protein.

Key words: asthma, rat, GROa protein, polymorphonuclear leukocyte, immunohistochemical method, dex amet hasone

CLC Number:

R965.2

LUO Li-dan, JIN Xiao-hong, TONG Xia-sheng, WANG En-zhi, GUO Hai-yuan, RUAN Zheng-ying, YE Hui. Expression of Grouth- Related Oncogen-a protein in rat asthma model and effects of dex amethasone[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(4): 396-400.

References

[1] National Insti tutes of Health National Heart,lung,and Blood Institute. NHLBI/WHO workshop report:global strategy for asthma management and prevention[M]. Revised,2007:7.
[2] 林剑.中性粒细胞在支气管哮喘发病机制中的作用[J]. 国外医学儿科学分册,2001,28(1):22-24.
[3] 童夏生,李昌崇,李绍波.中性粒细胞及其CD11b在大鼠哮喘中的表达及地塞米松调控[J].温州医学院学报,2005,35(3):207--210.
[4] 阮正英,李昌崇,童夏生,等.髓过氧化物酶、CD1lb和IL--8在大鼠哮喘模型中表达增加[J].基础医学与临床,2006,26(4):400-404.
[5] 叶辉,李昌崇,陈利中,等.布地奈德对哮喘大鼠碱性成纤维细胞生长因子蛋白和mRNA表达的影响[J].中国临床药理学与治疗学,2006,11(7):739-742.
[6] Baggiolini M. Chemoki nes and leukocyte trafid[J]. Na-ture,1998,392(6678):565-568.
[7] 倪翼,熊思乐.GRO家族:与细胞生长相关的趋化因子[J].生命的化学,2002,22(1):8-10.
[8] 李昌崇,童夏生,阮正英,等.中性粒细胞弹性蛋白酶和IL8在大鼠哮喘中的作用及地塞米松调控[J]. 中华微生物学和免疫学杂志,2005,25(9):737-741.
[9] Michalec L,Choudhury BK,Postlethwait E,et al. CCL7 and CXCL10 orchestrate oxidative st ress induced neutrophilic lung inflammation[J]. J Immunol,2002,168(2):846-852.
[10] Jarai G,Sukkar M,Garnett S,et al. Fffects of interleur-kin lbeta,interleukin-13 and transfom ing growth factor beta on gene expression in human airw ay smooth muscle using gene micrnarays[J]. Eur J Phamacol,2004,497(3):255-265.
[11] Kawaguchi M,Kokubu F,Matsukura S,et al. Inductionof GX-C chemokines,growth-rel ated onoogene alpha epression,and qithelial cell-derived neutophil acivating protein78 by ML1 (intereukin-17F) involves activation of Rafl-mi togen activated protein kinase kinase ext race lular signal-regulated kinase 1/2 pathway[J].J Phammacol Exp Ther,2003,307(3):1213-1220.

[1]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[2]	CHEN Qun, ZHU Heping, YUAN Xiaolong. Analysis of 197 cases of pentoxifylline injection and exploring supervision mode of rational drug use in hospitals [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 948-953.
[3]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[4]	XU Xiuhe, HE Xiaoli, ZHOU Jiashun, PAN Lizhu, ZHOU Zhuojun, LI Jiayue, WANG Caixia, YUAN Wei, ZHU Guiqi. Effects of scacia honey on serum uric acid level and renal injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 743-750.
[5]	WANG Lin, YU Jianguo, LI Xiao, LUAN Jiajie. Establish and implement a pre-prescription system for outpatient based on Six Sigma DMAIC model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 780-787.
[6]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[7]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[8]	LI Hongqin, CAO Limin, JIN Manyi, WANG Jianlong, CHAI Xiaoping, TIAN Miaomiao. Effects of different dosage forms of Qianzheng powder on facial nerve injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 617-623.
[9]	ZHANG Wei, LIU Lei, GUAN Shaoyang, SHENG Zhao, SUN Wenwen. Analysis of the diagnostic value of fine-needle aspiration cytology and BRAF and RAS gene mutation screening for thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 653-657.
[10]	WU Xiongzhi, WANG Xuan, XU Siqi, JU Xia, WANG Shengbin, CHEN Yongquan. A comparative investigation of the impact of oral midazolam solution and dexmedetomidine nasal spray on preoperative anxiety in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 666-670.
[11]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[12]	CHEN Cheng, DENG Yu, GONG Youlan, ZHANG Zhenming, DUAN Wulei, QING Jun, ZHANG Bo. Research progress of the classical TCM formula Huaihua powder [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 697-704.
[13]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[14]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[15]	DANG Zilong, LIU Haiyang, ZHANG Yangfan, LIU Jinfeng, ZHANG Tianwei, LI Bin, GUO Hong, CHENG Wenyuan, XU Xiaohui, LI Yile, WEI Yuhui, WU Xin'an. Optimization strategy of antibiotic dosing regimen in intensive care unit patients with augmented renal clearance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 561-571.